Company: PFSA
Filing Date: 2025-09-17
Form Type: S-1/A
Source: 0001213900-25-088333
Chunk: 17

Company: Profusa, Inc.
Filing Date: 2025-09-17
Form: S-1/A
Chunk 17
---
; •addressing any competing technological and market developments; •negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; •establishing and maintaining manufacturing facilities; •establishing and maintaining distribution relationships with third -partiesthat can provide adequate (in amount and quality) infrastructure to support market demand for our products; and •maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know -how. We have incurred significant losses in the past and will likely incur losses in the future. We have incurred significant operating losses in the past. We have financed our operations primarily through the issuance of equity and debt. We have devoted substantial resources to: •research and development relating to our Lumee Oxygen and Glucose Platform; •clinical studies for our Lumee Oxygen and Glucose Platform; •execution and maintenance of our intellectual property portfolio; •expenses associated with the commercialization of our Lumee Oxygen Platform; and •expansion of our workforce. We expect our research and development expenses to increase in connection with our continued clinical trials and other development activities related to our products. We also expect that our general and administrative expenses will continue to increase due, among other things, to our expansion of commercialization for the Lumee Oxygen and 9 Glucose Platform and the additional operational and regulatory burdens applicable to public healthcare and medical device companies. As a result, we will likely continue to incur operating losses in the future. These losses, among other things, may have an adverse effect on our stockholders’ equity. We may need to raise additional funding to expand the commercialization of our products and services and to expand our research and development efforts. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization or development efforts or other operations. Our operations have consumed substantial amounts of cash since inception. We expect to expend substantial additional amounts to commercialize our products and services and to develop new products and services. We expect to use the funds received in connection with the Business Combination to scale our operations, develop new products and services, expand internationally, and for working capital and general corporate purposes. We may require additional capital to conduct clinical trials, expand the commercialization of our existing product and services and to develop new products and services. In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner